鲁妥珠单抗

化合物

鲁妥珠单抗INN:lumretuzumab;开发代号:RG7116),或译鲁姆妥珠单抗,是一种人源化HER3单克隆抗体,设计用于治疗癌症[1][2]

鲁妥珠单抗
单克隆抗体
种类完整抗体
目标HER3
临床资料
其他名称RG7116
ATC码
  • 未分配
识别信息
CAS号1448327-63-6
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6512H10064N1736O2052S44
摩尔质量146,916.88 g·mol−1

一项Ib/II期研究调查了在第一线治疗晚期或转移性鳞状非小细胞肺癌(sqNSCLC)患者时,鲁妥珠单抗与卡铂紫杉醇联合使用的安全性和临床活性。[3]

该药物由基因泰克/罗氏公司开发。

参考资料

编辑
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lumretuzumab, American Medical Association.
  2. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2). 
  3. ^ Cejalvo, Juan-Miguel; Jacob, Wolfgang; Fleitas Kanonnikoff, Tania; Felip, Enriqueta; Navarro Mendivil, Alejandro; Martinez Garcia, Maria; Taus Garcia, Alvaro; Leighl, Natasha; Lassen, Ulrik; Mau-Soerensen, Morten; Adessi, Celine. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open. 2019, 4 (4). doi:10.1136/esmoopen-2019-000532 (英语).